Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vincristine liposomal - Acrotech Biopharma

Next Previous
Drug Profile

Vincristine liposomal - Acrotech Biopharma

Alternative Names: Marqibo; Sphingosomal vincristine; Vincacine; Vincristine sulfate injection; Vincristine sulfate liposomes injection; VSLI

Latest Information Update: 20 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Acrotech Biopharma; CASI Pharmaceuticals; Hana Biosciences; Inex Pharmaceuticals Corporation; Talon Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Vinca alkaloids
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase I/II Cancer
  • Discontinued Colorectal cancer; Malignant melanoma; Multiple myeloma; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 12 Jun 2025 Efficacy and adverse events data from a phase III Optimal>60 trial in Non-Hodgkin's lymphoma presented at the 30th Congress of the European Haematology Association (EHA-2025)
  • 12 Jun 2025 Efficacy and adverse events data from a phase III trial in Non-Hodgkin's lymphoma presented at the 30th Congress of the European Haematology Association (EHA-2025)
  • 18 Jan 2024 Spectrum Pharmaceuticals completes a phase III trial in Non-Hodgkin's lymphoma (combination therapy, first-line therapy) in elderly patients in Germany (IV) (NCT01478542)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top